Global Cancer Diagnostics Market Trend and Development Strategy Analysis 2023-2029

Report ID: ARS10815 | Category: Healthcare | Pages: 109 | Format: PDF | Published Date: December 18,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$2950.00 Multi User-$5500.00

Report Description
View Table of Contents

Report Summary

Market Analysis and Insights: Global Cancer Diagnostics Market
The global Cancer Diagnostics market size in 2022 is 16700.0 million US dollars, and it is expected to be 28069.0 million US dollars by 2029, with a compound annual growth rate of 7.70% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:
The main players in the Cancer Diagnostics market include Abbott. (U.S.), DiagnoCure Inc. (Canada), Thermo Fisher Scientific (U.S.), Illumina, Inc. (U.S.), and QIAGEN (Germany). The share of the top 3 players in the Cancer Diagnostics market is XX%.

REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Cancer Diagnostics market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:
The report segments the market by Type and Application. Imaging Testing accounted for XX% of Cancer Diagnostics market in 2022. Biomarkers Testing share of XX%.
Diagnostic Centres accounted for XX% of the Cancer Diagnostics market in 2022. Hospitals and Clinics accounts for XX%.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer Diagnostics market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Diagnostics market.

Global Cancer Diagnostics Scope and Market Size
Cancer Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource.

The impact of the outbreak of COVID-19 and the Russia-Ukraine War on the Cancer Diagnostics industry is considered in the report, covering the dynamic analysis of the development of the Cancer Diagnostics industry, including trends, technologies, opportunities, constraints. To ensure report buyers are able to gain in-depth knowledge of the market.

Chapter Outline
Chapter 1: Introduces the product overview, market scope, economic analysis of global regions, and industry dynamic analysis, and then includes inflation analysis, the impact of the Russo-Ukrainian war on the market, and the global impact of the coronavirus disease (COVID-19).
Chapters 2-4: Segmented the global Cancer Diagnostics market by type, application and region. Analyze the revenue of market segments from different perspectives.
Chapters 5-9: Provide North America, Europe, Asia-Pacific, Latin America and Middle East & Africa Cancer Diagnostics market country revenue data, and includes PEST Analysis.
Chapter 10: Analysis of the competitive environment of Cancer Diagnostics market participants. This mainly includes the revenue and market share of the top players, along with the players' M&A and new entrants and expansion plans.
Chapter 11: Analyzes the main companies in the Cancer Diagnostics industry, including their main businesses, products/services, revenue, gross margin, and the latest developments.
Chapters 12-14: Provide detailed Cancer Diagnostics market forecast data, broken down by type, application, and region to help understand future growth trends.
Chapter 15: Concludes with an explanation of the data sources and research methods.

Highlights-Regions

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Spain
Nordic
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Egypt
South Africa
UAE
Turkey
Saudi Arabia

Player list
Abbott. (U.S.)
DiagnoCure Inc. (Canada)
Thermo Fisher Scientific (U.S.)
Illumina, Inc. (U.S.)
QIAGEN (Germany)
F. Hoffmann-La Roche Ltd (Switzerland)
Agilent Technologies, Inc. (U.S.)
Quest Diagnostics Incorporated. (U.S.)
Merck KGaA, (Germany)
Hologic, Inc. (U.S.)
BD. (U.S.)
GSK plc. (U.K.)
Novartis AG (Switzerland)
Bristol-Myers Squibb Company (U.S.)
Lilly (U.S.)
Pfizer, Inc. (U.S.)
Genomic Health, Inc. (U.S.)
bioMérieux SA (France)
Astellas Pharma Inc. (Japan)
Myriad Genetics, Inc. (U.S.)

Types list
Imaging Testing
Biomarkers Testing
In Vitro Diagnostic Testing
Biopsy
Others

Application list
Diagnostic Centres
Hospitals and Clinics
Research Institutes
Others

Table of Content

1 Cancer Diagnostics Market Introduction and Overview
1.1 Cancer Diagnostics Definition
1.2 Research Purposes
1.3 Report Timeline
1.4 Economic Analysis of Global Regions
1.5 Cancer Diagnostics Industry Dynamic Analysis
1.5.1 Cancer Diagnostics Market Trends Analysis
1.5.2 Cancer Diagnostics Market Drivers Analysis
1.5.3 Cancer Diagnostics Market Challenges Analysis
1.5.4 Cancer Diagnostics Market Restraints Analysis
1.6 Inflation Analysis
1.7 The Impact of the Russian-Ukrainian War on the Market
1.8 Coronavirus Disease 2020 (COVID-19) Impact on Global
2 Global Cancer Diagnostics Market Insights by Type
2.1 Market Size Insights by Types
2.2 Global Cancer Diagnostics Revenue and Share by Type
3 Global Cancer Diagnostics Market Insights by Application
3.1 Market Size Insights by Application
3.2 Global Cancer Diagnostics Revenue and Share by Application (2018-2023)
4 Global Market Growth Insights
4.1 Global Cancer Diagnostics Market Size (2018-2023)
4.2 Cancer Diagnostics Growth Insights by Regions
4.2.1 Cancer Diagnostics Market Size by Regions: 2018 VS 2023 VS 2029
4.2.2 Cancer Diagnostics Revenue Market Size by Regions (2018-2023)
4.2.3 North America Cancer Diagnostics Market Size (2018-2023)
4.2.4 Europe Cancer Diagnostics Market Size (2018-2023)
4.2.5 Asia-Pacific Cancer Diagnostics Market Size (2018-2023)
4.2.6 Latin America Cancer Diagnostics Market Size (2018-2023)
4.2.7 Middle East & Africa Cancer Diagnostics Market Size (2018-2023)
5 North America
5.1 North America Cancer Diagnostics Revenue by Countries
5.1.1 North America Cancer Diagnostics Revenue by Countries (2018-2023)
5.2 North America PEST Analysis
5.3 United States
5.4 Canada
6 Asia Pacific
6.1 Asia Pacific Cancer Diagnostics Revenue by Countries
6.1.1 Asia Pacific Cancer Diagnostics Revenue by Countries (2018-2023)
6.2 Asia-Pacific PEST Analysis
6.3 China
6.4 Japan
6.5 Korea
6.6 Southeast Asia
6.7 India
6.8 Australia
7 Europe
7.1 Europe Cancer Diagnostics Revenue by Countries
7.1.1 Europe Cancer Diagnostics Revenue by Countries (2018-2023)
7.2 Europe PEST Analysis
7.3 Germany
7.4 France
7.5 UK
7.6 Italy
7.7 Russia
7.8 Spain
7.9 Nordic
8 Latin America
8.1 Latin America Cancer Diagnostics Revenue by Countries
8.1.1 Latin America Cancer Diagnostics Revenue by Countries (2018-2023)
8.2 Latin America PEST Analysis
8.3 Brazil
8.4 Argentina
8.5 Mexico
9 Middle East & Africa
9.1 Middle East & Africa Cancer Diagnostics Revenue by Countries
9.1.1 Middle East & Africa Cancer Diagnostics Revenue by Countries (2018-2023)
9.2 Middle East & Africa PEST Analysis
9.3 Egypt
9.4 South Africa
9.5 UAE
9.6 Turkey
9.7 Saudi Arabia
10 Global Cancer Diagnostics Market Competition, by Players
10.1 Global Cancer Diagnostics Revenue and Market Share by Players
10.2 Market Concentration Rate
10.2.1 Top 3 Cancer Diagnostics Players Market Share in 2022
10.2.2 Top 6 Cancer Diagnostics Players Market Share in 2022
10.2.3 Market Competition Trend
10.3 Cancer Diagnostics Players Head Office, Business Provided
10.4 Cancer Diagnostics Mergers & Acquisitions
10.5 Cancer Diagnostics New Entrants and Expansion Plans
11 Players Profiles
11.1  Abbott. (U.S.)
11.1.1 Abbott. (U.S.) Company Profile
11.1.2 Cancer Diagnostics Product Overview
11.1.3 Abbott. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.1.4 Abbott. (U.S.) Business Overview
11.1.5 Recent Developments and Plans
11.2  DiagnoCure Inc. (Canada)
11.2.1 DiagnoCure Inc. (Canada) Company Profile
11.2.2 Cancer Diagnostics Product Overview
11.2.3 DiagnoCure Inc. (Canada) Cancer Diagnostics Market Performance (2018-2023)
11.2.4 DiagnoCure Inc. (Canada) Business Overview
11.2.5 Recent Developments and Plans
11.3  Thermo Fisher Scientific (U.S.)
11.3.1 Thermo Fisher Scientific (U.S.) Company Profile
11.3.2 Cancer Diagnostics Product Overview
11.3.3 Thermo Fisher Scientific (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.3.4 Thermo Fisher Scientific (U.S.) Business Overview
11.3.5 Recent Developments and Plans
11.4  Illumina, Inc. (U.S.)
11.4.1 Illumina, Inc. (U.S.) Company Profile
11.4.2 Cancer Diagnostics Product Overview
11.4.3 Illumina, Inc. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.4.4 Illumina, Inc. (U.S.) Business Overview
11.4.5 Recent Developments and Plans
11.5  QIAGEN (Germany)
11.5.1 QIAGEN (Germany) Company Profile
11.5.2 Cancer Diagnostics Product Overview
11.5.3 QIAGEN (Germany) Cancer Diagnostics Market Performance (2018-2023)
11.5.4 QIAGEN (Germany) Business Overview
11.5.5 Recent Developments and Plans
11.6  F. Hoffmann-La Roche Ltd (Switzerland)
11.6.1 F. Hoffmann-La Roche Ltd (Switzerland) Company Profile
11.6.2 Cancer Diagnostics Product Overview
11.6.3 F. Hoffmann-La Roche Ltd (Switzerland) Cancer Diagnostics Market Performance (2018-2023)
11.6.4 F. Hoffmann-La Roche Ltd (Switzerland) Business Overview
11.6.5 Recent Developments and Plans
11.7  Agilent Technologies, Inc. (U.S.)
11.7.1 Agilent Technologies, Inc. (U.S.) Company Profile
11.7.2 Cancer Diagnostics Product Overview
11.7.3 Agilent Technologies, Inc. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.7.4 Agilent Technologies, Inc. (U.S.) Business Overview
11.7.5 Recent Developments and Plans
11.8  Quest Diagnostics Incorporated. (U.S.)
11.8.1 Quest Diagnostics Incorporated. (U.S.) Company Profile
11.8.2 Cancer Diagnostics Product Overview
11.8.3 Quest Diagnostics Incorporated. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.8.4 Quest Diagnostics Incorporated. (U.S.) Business Overview
11.8.5 Recent Developments and Plans
11.9  Merck KGaA, (Germany)
11.9.1 Merck KGaA, (Germany) Company Profile
11.9.2 Cancer Diagnostics Product Overview
11.9.3 Merck KGaA, (Germany) Cancer Diagnostics Market Performance (2018-2023)
11.9.4 Merck KGaA, (Germany) Business Overview
11.9.5 Recent Developments and Plans
11.10  Hologic, Inc. (U.S.)
11.10.1 Hologic, Inc. (U.S.) Company Profile
11.10.2 Cancer Diagnostics Product Overview
11.10.3 Hologic, Inc. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.10.4 Hologic, Inc. (U.S.) Business Overview
11.10.5 Recent Developments and Plans
11.11  BD. (U.S.)
11.11.1 BD. (U.S.) Company Profile
11.11.2 Cancer Diagnostics Product Overview
11.11.3 BD. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.11.4 BD. (U.S.) Business Overview
11.11.5 Recent Developments and Plans
11.12  GSK plc. (U.K.)
11.12.1 GSK plc. (U.K.) Company Profile
11.12.2 Cancer Diagnostics Product Overview
11.12.3 GSK plc. (U.K.) Cancer Diagnostics Market Performance (2018-2023)
11.12.4 GSK plc. (U.K.) Business Overview
11.12.5 Recent Developments and Plans
11.13  Novartis AG (Switzerland)
11.13.1 Novartis AG (Switzerland) Company Profile
11.13.2 Cancer Diagnostics Product Overview
11.13.3 Novartis AG (Switzerland) Cancer Diagnostics Market Performance (2018-2023)
11.13.4 Novartis AG (Switzerland) Business Overview
11.13.5 Recent Developments and Plans
11.14  Bristol-Myers Squibb Company (U.S.)
11.14.1 Bristol-Myers Squibb Company (U.S.) Company Profile
11.14.2 Cancer Diagnostics Product Overview
11.14.3 Bristol-Myers Squibb Company (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.14.4 Bristol-Myers Squibb Company (U.S.) Business Overview
11.14.5 Recent Developments and Plans
11.15  Lilly (U.S.)
11.15.1 Lilly (U.S.) Company Profile
11.15.2 Cancer Diagnostics Product Overview
11.15.3 Lilly (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.15.4 Lilly (U.S.) Business Overview
11.15.5 Recent Developments and Plans
11.16  Pfizer, Inc. (U.S.)
11.16.1 Pfizer, Inc. (U.S.) Company Profile
11.16.2 Cancer Diagnostics Product Overview
11.16.3 Pfizer, Inc. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.16.4 Pfizer, Inc. (U.S.) Business Overview
11.16.5 Recent Developments and Plans
11.17  Genomic Health, Inc. (U.S.)
11.17.1 Genomic Health, Inc. (U.S.) Company Profile
11.17.2 Cancer Diagnostics Product Overview
11.17.3 Genomic Health, Inc. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.17.4 Genomic Health, Inc. (U.S.) Business Overview
11.17.5 Recent Developments and Plans
11.18  bioMérieux SA (France)
11.18.1 bioMérieux SA (France) Company Profile
11.18.2 Cancer Diagnostics Product Overview
11.18.3 bioMérieux SA (France) Cancer Diagnostics Market Performance (2018-2023)
11.18.4 bioMérieux SA (France) Business Overview
11.18.5 Recent Developments and Plans
11.19  Astellas Pharma Inc. (Japan)
11.19.1 Astellas Pharma Inc. (Japan) Company Profile
11.19.2 Cancer Diagnostics Product Overview
11.19.3 Astellas Pharma Inc. (Japan) Cancer Diagnostics Market Performance (2018-2023)
11.19.4 Astellas Pharma Inc. (Japan) Business Overview
11.19.5 Recent Developments and Plans
11.20  Myriad Genetics, Inc. (U.S.)
11.20.1 Myriad Genetics, Inc. (U.S.) Company Profile
11.20.2 Cancer Diagnostics Product Overview
11.20.3 Myriad Genetics, Inc. (U.S.) Cancer Diagnostics Market Performance (2018-2023)
11.20.4 Myriad Genetics, Inc. (U.S.) Business Overview
11.20.5 Recent Developments and Plans
12 Global Cancer Diagnostics Forecast Market Insights by Type
12.1 Global Cancer Diagnostics Revenue Market Forecast by Type (2023-2029)
13 Global Cancer Diagnostics Forecast Market Insights by Application
13.1 Cancer Diagnostics Revenue Market Forecast by Application (2023-2029)
14 Global Market Growth Forecast Insights
14.1 Global Cancer Diagnostics Forecast Market Size (2023-2029)
14.2 Cancer Diagnostics Growth Forecast Insights by Regions
14.2.1 Cancer Diagnostics Revenue Forecast Market Size by Regions (2023-2029)
14.2.2 North America Cancer Diagnostics Forecast Market Size (2023-2029)
14.2.3 Europe Cancer Diagnostics Forecast Market Size (2023-2029)
14.2.4 Asia-Pacific Cancer Diagnostics Forecast Market Size (2023-2029)
14.2.5 Latin America Cancer Diagnostics Forecast Market Size (2023-2029)
14.2.6 Middle East & Africa Cancer Diagnostics Forecast Market Size (2023-2029)
15 Methodology and Data Source
15.1 A Methodology
15.1.1 Research Process
15.1.2 Market Size Estimation
15.1.3 Market Breakdown and Data Triangulation
15.2 B Data Source
15.2.1 Legal Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Cancer Diagnostics Market Trend and Development Strategy Analysis 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?